type 2 diabetes complicated nonalcoholic fatty liver disease
Conditions
Interventions
Groop Exenatide:Exenatide was initiated at 5 mcg twice daily while stopping their pre-study oral hypoglycemic drugs or taking them at reduced dose, titrated to 10 mcg twice daily after one month
Groop Glargine:Glargine was started with 0.1IU/kg once-daily at bedtime while continuing their pre-study oral hypoglycemic drugs, and titrated with glucose levels
Sponsors
Metabolic Disease Hospital of Tianjin Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Elderly patients with type 2 diabetes (age 60~75 years); 2. Diagnosis of fatty liver by ultrasound; 3. Inadequate glycaemic control (FPG: 8.0-11.0 mmol/L and/or HbAlc: 7.5%-10.0%); 4. Alanine aminotransferase and aspartate aminotransferase twice below the upper normal limit.
Exclusion criteria
Exclusion criteria: 1. Type 1 diabetes or secondary diabetes; 2. With severe acute or chronic diabetes complications; 3. Clinically significant haematologic, oncologic, renal, cardiac, hepatic or gastrointestinal disease; 4. Any history of liver disease including metabolic or auto-immune liver disease or viral hepatitis; 5. Weekly alcohol intake >14 units for women or >21 units for men.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| markers of hepatic function;the controlled attenuation parameter (CAP);glycosylated hemoglobin;fasting plasma glucose.;postprandial plasma glucose; | — |
Secondary
| Measure | Time frame |
|---|---|
| blood lipid; | — |
Countries
China
Contacts
Public ContactGUANYUE
Outcome results
None listed